Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:VNDA News 31 December 2025 - 1 January 2026

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

NEW YORK, January 1, 2026, 13:41 ET — Market closed Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq The moves matter because regulatory calls can dominate small-cap biotech even when the broader healthcare sector trades like a defensive corner of the market. Investors also head into January watching how rates and earnings guidance reshape valuations after thin year-end trading. In Wednesday’s final session of 2025, the Health Care Select Sector SPDR Fund (XLV) fell
1 January 2026
··
Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

NEW YORK, January 1, 2026, 08:07 ET — Market closed U.S. stock markets are closed on Thursday for New Year’s Day after the Nasdaq Composite slipped 0.8% in the final session of 2025, ending at 23,241.99. The S&P 500 fell 0.7% to 6,845.50 and the Dow Jones Industrial Average lost 0.6% to 48,063.29. AP News+1 The timing matters because the Nasdaq heads into 2026 near record territory after a year in which bets on artificial intelligence powered many of the biggest winners. The late-year dip is the first signal investors will test against hard data on inflation, the labor market
1 January 2026
····
Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

NEW YORK, December 31, 2025, 13:38 ET — Regular session Vanda Pharmaceuticals shares jumped 28.1% to $9.01 at 1:38 p.m. ET on Wednesday after the company said the U.S. Food and Drug Administration approved Nereus (tradipitant) to prevent vomiting induced by motion. Vanda said the oral drug is a neurokinin-1 (NK-1) receptor antagonist — meaning it blocks a receptor involved in nausea signaling — and called it the first new pharmacologic motion-sickness treatment in more than four decades. In late-stage Phase 3 trials — the final stage before approval — vomiting rates were about 10%–20% on Nereus versus 38%–44% on
31 December 2025
·
S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

NEW YORK, December 31, 2025, 1:26 PM ET — Regular session U.S. stocks edged lower on Wednesday in thin year-end trading. The Dow Jones Industrial Average fell 114.33 points, or 0.24%, to 48,252.73; the S&P 500 lost 16.62 points, or 0.24%, to 6,879.62; and the Nasdaq Composite slipped 51.05 points, or 0.22%, to 23,368.03. Reuters The drift lower on the last trading day of 2025 followed a run to record highs that left the major indexes on track to post double-digit gains for the year. Tech led the declines — with Microsoft and Apple among the biggest weights — and
31 December 2025
··
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

NEW YORK, December 31, 2025, 04:27 ET — Premarket Vanda Pharmaceuticals’ shares surged about 18% in premarket trading on Wednesday after the U.S. Food and Drug Administration approved its motion-sickness vomiting drug, Nereus (tradipitant). StockAnalysis+1 The approval matters now because Vanda is moving from a long-running regulatory story to a commercial one, with investors shifting quickly to questions of launch execution, insurance coverage and pricing. The company said it expects to launch Nereus in the coming months. Reuters+1 It also gives Vanda a fresh catalyst heading into year-end trading, when extended-hours moves can be amplified by thinner liquidity. Shares closed
31 December 2025
···

Stock Market Today

Bitcoin price wobbles below $69,000 on weekend — what matters before Monday’s reopen

Bitcoin price wobbles below $69,000 on weekend — what matters before Monday’s reopen

7 February 2026
Bitcoin fell 1.1% to $68,917 Saturday after volatile trading, while Ether held near $2,036. U.S. spot bitcoin ETFs saw $330.7 million in net inflows on Feb. 6, reversing outflows the previous day. Strategy shares rebounded after hitting a low of $111.27 Thursday. Traders are watching Monday’s U.S. market open and the upcoming inflation report for direction.
XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Go toTop